Heterozygous NFKB1 variant causes inflammatory dysregulation shaped by broader genetic context in common variable immunodeficiency
Authors:
- Kevin M. HayesKevin M. Hayes
- Kai BoldtKai Boldt
- Peter J. SchnorrPeter J. Schnorr
- Pushpinder BawaPushpinder Bawa
- Miranda L. AbyaziMiranda L. Abyazi
- Matthew S. WareMatthew S. Ware
- Gavin GyimesiGavin Gyimesi
- Marianne JamesMarianne James
- Huaibin M. KoHuaibin M. Ko
- Charlotte Cunningham-RundlesCharlotte Cunningham-Rundles
- Joseph P. MizgerdJoseph P. Mizgerd
- Gustavo MostoslavskyGustavo Mostoslavsky
Open Access
- 23 March 2026
- journal article
- case report
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (6)
Abstract
Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary antibody deficiency. For unclear reasons, inflammatory complications, like gastrointestinal (GI) disease, occur in ~50% of CVID cases, worsening morbidity and mortality. NFKB1 variants are among the most frequent genetic variants in CVID. While effect of NFKB1 variants is not well understood, we previously found frameshift heterozygous NFKB1 variants to increase cytokines, monocytes, and inflammatory complications in CVID. In this report, we used induced pluripotent stem cell–derived (iPSC-derived) monocytes (iMONOs) with CRISPR/Cas9-mediated gene editing to study a heterozygous NFKB1 frameshift found in a patient with CVID with severe GI disease. The heterozygous NFKB1 variant similarly reduced NFKB1 protein in CVID patient– and healthy donor–derived iMONOs, but elevated LPS-induced IL-1β release and expression of inflammatory genes, including IL1B , IL6 , TNF , and neutrophil chemoattractants, only in CVID patient iMONOs. CVID patient iMONOs also had elevations of IL-12, CCL4, and CCL12 unaffected by presence or absence of the NFKB1 variant. TNF antagonism improved the patient’s GI disease, diminishing neutrophilic gastritis, circulating neutrophils, and the neutrophil chemoattractant CXCL1 in the blood. While the biology remains complex, our approach found heterozygous NFKB1 variant–induced inflammatory changes intensified in CVID iMONOs, corresponding with clinical response to TNF antagonism.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (AI137187)
- National Institute of Allergy and Infectious Diseases (AI151486)
- National Heart, Lung, and Blood Institute (HL007035)
- National Heart, Lung, and Blood Institute (HL095993)
- National Heart, Lung, and Blood Institute (HL170952)
- Norges Idrettshøgskole (N01 75N92025R00004)
- Candace and Barry Sloane Charitable Foundation (philantropy)
- American Academy of Allergy, Asthma and Immunology Foundation (Faculty Development Award)
This publication has 64 references indexed in Scilit:
- Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert CommitteeJournal of Clinical Immunology, 2022
- Intravenous Immunoglobulins Promote an Expansion of Monocytic Myeloid-Derived Suppressor Cells (MDSC) in CVID PatientsJournal of Clinical Immunology, 2022
- Inflammasome activation: from molecular mechanisms to autoinflammationClinical & Translational Immunology, 2022
- State-of-the-art diagnostic evaluation of common variable immunodeficiencyAnnals of Allergy, Asthma & Immunology, 2021
- Perspective: Evolving Concepts in the Diagnosis and Understanding of Common Variable Immunodeficiency Disorders (CVID)Clinical Reviews in Allergy & Immunology, 2019
- Generation of Human Induced Pluripotent Stem Cells Using a Defined, Feeder‐Free Reprogramming SystemCurrent Protocols in Stem Cell Biology, 2018
- Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of TreatmentJournal of Clinical Immunology, 2017
- Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable ImmunodeficiencyThe American Journal of Human Genetics, 2015
- CRISPR/Cas9‐Directed Genome Editing of Cultured CellsCurrent Protocols in Molecular Biology, 2014
- A clinical perspective of IL‐1β as the gatekeeper of inflammationEuropean Journal of Immunology, 2011